Evidence map›Paper›PMID 28371433›Full record

Trial reportAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2017

Urinary Markers of Fibrosis and Risk of Cardiovascular Events and Death in Kidney Transplant Recipients: The FAVORIT Trial.

M Park, R Katz, M G Shlipak, D Weiner, R Tracy, V Jotwani, J Hughes-Austin, F Gabbai, C Y Hsu, M Pfeffer and 6 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 42 citations in OpenAlex.

  1. Trial
  2. Association of Urine Biomarkers of Kidney Tubule Injury and Dysfunction With Frailty Index and Cognitive Function in Persons With CKD in SPRINT.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2021
    Trial
  3. Trial
  4. Trial
  5. Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2019
    Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. The Promise of Tubule Biomarkers in Kidney Disease: A Review.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2021
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 1 country.

M ParkDivision of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, CA.
R KatzKidney Research Institute, Division of Nephrology, University of Washington, Seattle, WA.
M G ShlipakDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA.
D WeinerDivision of Nephrology, Department of Medicine, Tufts Medical Center, Boston, MA.
R TracyDepartment of Pathology, University of Vermont, Burlington, VT.
V JotwaniDivision of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, CA.
J Hughes-AustinDivision of Preventive Medicine, Department of Preventive Medicine and Public Health, University of California San Diego, San Diego, CA.
F GabbaiDivision of Nephrology-Hypertension, Department of Medicine, University of California San Diego, San Diego, CA.
C Y HsuDivision of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, CA.
M PfefferDivision of Cardiology, Brigham and Women's Hospital, Boston, MA.
N BansalKidney Research Institute, Division of Nephrology, University of Washington, Seattle, WA.
A BostomRhode Island Hospital, Providence, RI.
O GutierrezDepartments of Medicine and Epidemiology, University of Alabama at Birmingham, Birmingham, AL.
M SarnakDivision of Nephrology, Department of Medicine, Tufts Medical Center, Boston, MA.
A LeveyDivision of Nephrology, Department of Medicine, Tufts Medical Center, Boston, MA.
J H IxDivision of Preventive Medicine, Department of Preventive Medicine and Public Health, University of California San Diego, San Diego, CA.
Tufts Medical Center · USUniversity of California, San Francisco · USUniversity of California, San Diego · USUniversity of Washington · USBrigham and Women's Hospital · USRhode Island Hospital · USSan Francisco VA Medical Center · USUniversity of Alabama at Birmingham · USUniversity of Vermont · USVA San Diego Healthcare System · US

Funding

Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) TrialU01DK061700 · NIDDK · TUFTS MEDICAL CENTER · PI BOSTOM, ANDREW G. · 2001 to 2011
$29.0M
Kidney Tubular Damage and Dysfunction Identify a Novel Axis of Chronic Kidney DiseaseR01DK098234 · NIDDK · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI IX, JOACHIM H, SHLIPAK, MICHAEL G · 2014 to 2023
$5.6M
Patient Oriented Research in Kidney DiseaseK24DK092291 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSU, CHI-YUAN · 2011 to 2020
$1.2M
Biomarkers of Drug-induced Kidney Injury in HIVK23DK109868 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOTWANI, VASANTHA KOLAVENNU · 2016 to 2020
$993k
Why do patients with cardiovascular disease develop kidney injury and disease?K23DK099238 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PARK, MEYEON · 2013 to 2017
$928k
Mentored Patient Oriented Research in Kidney DiseaseK24DK110427 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI IX, JOACHIM H · 2016 to 2020
$780k
NIDDK NIH HHS K23 DK099238NIDDK NIH HHS K23 DK109868NIDDK NIH HHS K24 DK092291NIDDK NIH HHS K24 DK110427NIDDK NIH HHS R01 DK098234NIDDK NIH HHS U01 DK061700
6 · The paper itself

Abstract

Cardiovascular risk remains high in kidney transplant recipients (KTRs) despite improved kidney function after transplant. Urinary markers of kidney fibrosis and injury may help to reveal mechanisms of this risk. In a case-cohort study among stable KTRs who participated in the FAVORIT trial, we measured four urinary proteins known to correlate with kidney tubulointerstitial fibrosis on biopsy (urine alpha 1 microglobulin [α1m], monocyte chemoattractant protein-1 [MCP-1], procollagen type I [PINP] and type III [PIIINP] N-terminal amino peptide) and evaluated associations with cardiovascular disease (CVD) events (n = 300) and death (n = 371). In adjusted models, higher urine α1m (hazard ratio [HR] per doubling of biomarker 1.40 [95% confidence interval [CI] 1.21, 1.62]), MCP-1 (HR 1.18 [1.03, 1.36]), and PINP (HR 1.13 [95% CI 1.03, 1.23]) were associated with CVD events. These three markers were also associated with death (HR per doubling α1m 1.51 [95% CI 1.32, 1.72]; MCP-1 1.31 [95% CI 1.13, 1.51]; PINP 1.11 [95% CI 1.03, 1.20]). Higher concentrations of urine α1m, MCP-1, and PINP may identify KTRs at higher risk for CVD events and death. These markers may identify a systemic process of fibrosis involving both the kidney and cardiovascular system, and give new insights into mechanisms linking the kidney with CVD.

Indexed as

Kidney TransplantationAgedBiomarkersCardiovascular DiseasesCase-Control StudiesFemaleFibrosisFolic AcidHumansMaleMiddle AgedNephritis, InterstitialRisk FactorsBiomarkersFolic Acidbiomarkercardiovascular diseaseclinical research/practicekidney diseasekidney transplantation/nephrology

Identifiers

PMID28371433
PMCPMC5620109
OpenAlexW2598290521

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.